AKRO - NASDAQ

Akero Therapeutics, Inc.

AKRO·NASDAQ

$54.65

+0.0000%

HealthcareBiotechnology

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$4.50B

EPS-3.7500

P/E Ratio-14.57

Earnings Date02/27/2026

akro

Operating Expenses

Last Annual Value

285.42M

3-Year CAGR

41%

5-Year CAGR

44%

10-Year CAGR

51%

Adjust for Inflation

Akero Therapeutics, Inc. Competitors Analysis of Operating Expenses

AKRO · NASDAQ

Company	Operating Expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Akero Therapeutics, Inc. NASDAQ:AKRO	285.42M	18.2%	23.1%	N/A
Crinetics Pharmaceuticals, Inc. NASDAQ:CRNX	519.50M	31.9%	36.7%	56.1%
Soleno Therapeutics, Inc. NASDAQ:SLNO	172.75M	61.0%	40.5%	29.0%
ACADIA Pharmaceuticals Inc. NASDAQ:ACAD	877.70M	5.2%	6.7%	11.9%
Arcellx, Inc. NASDAQ:ACLX	268.69M	10.3%	32.8%	N/A
NewAmsterdam Pharma Company N.V. NASDAQ:NAMS	248.13M	8.0%	48.0%	N/A
Praxis Precision Medicines, Inc. NASDAQ:PRAX	326.06M	97.9%	14.3%	N/A
Viking Therapeutics, Inc. NASDAQ:VKTX	393.34M	57.4%	47.8%	39.7%
Immunovant, Inc. NASDAQ:IMVT	532.90M	36.8%	37.6%	N/A
Kymera Therapeutics, Inc. NASDAQ:KYMR	388.60M	16.8%	17.5%	N/A

Akero Therapeutics, Inc. Fair Value Envelope

AKRO · NASDAQ

Our analysis suggests that AKRO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $54.65, this represents a potential HIDDEN relative to our calculated worth for Akero Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $54.65

Related Guides

Blog Categories

Continue your AKRO research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.